scholarly journals Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders

2017 ◽  
Vol 55 (10) ◽  
pp. 2913-2923 ◽  
Author(s):  
J. U. H. Lam ◽  
M. Rebolj ◽  
D. M. Ejegod ◽  
H. Pedersen ◽  
C. Rygaard ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Reference Population ◽  
Hybrid Capture ◽  
Hpv Prevalence ◽  
Screening Participation ◽  
Hybrid Capture 2 ◽  
Management Of Hpv ◽  
Hpv Assays ◽  
Level Of Agreement

ABSTRACT The Copenhagen Self-Sampling Initiative (CSi) has shown how human papillomavirus (HPV)-based self-sampling can be used to increase screening participation among 23,632 nonattenders in the Capital Region of Denmark. In this study, we describe HPV prevalence and genotype frequency in 4,824 self-samples as determined by three HPV assays (the CLART, Onclarity, and Hybrid Capture 2 [HC2] assays) and compare the results with those for physician-taken follow-up samples. The HPV self-sample findings were also compared to the findings for a reference population of 3,347 routinely screened women from the Horizon study, which had been undertaken in the same screening laboratory. Nonattenders had an HPV prevalence of 11.3% as determined by the CLART assay, which was lower than that for women from the Horizon study (18.5%). One-third of the CSi women who tested HPV positive by self-sampling tested HPV negative on the physician-taken follow-up sample. The CLART and Onclarity assays agreed on 64% (95% confidence interval [CI], 60 to 68%) of the HPV-positive self-taken samples. When the HC2 assay results were added into a three-way comparison, the level of agreement decreased to 27% (95% CI, 24 to 29%). Our findings suggest that further validation of HPV assays on self-taken samples is needed for optimal HPV detection and correct clinical management of HPV-positive women.

scholarly journals Prevalence of Anal Human Papillomavirus (HPV) and Performance of Cepheid Xpert and Hybrid Capture 2 (hc2) HPV Assays in South African HIV-Infected Women

2017 ◽  
Vol 148 (2) ◽  
pp. 148-153 ◽  
Author(s):  
Zizipho Z. A. Mbulawa ◽  
Timothy Wilkin ◽  
Bridgette J. Goeieman ◽  
Eefje Jong ◽  
Pamela Michelow ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
South African ◽  
Hybrid Capture ◽  
Hybrid Capture 2 ◽  
And Performance ◽  
Hpv Assays

scholarly journals Clinical Performance of Hybrid Capture 2 Human Papillomavirus Testing for Recurrent High-Grade Cervical/Vaginal Intraepithelial Neoplasm in Patients With an ASC-US Papanicolaou Test Result During Long-Term Posttherapy Follow-up Monitoring

2015 ◽  
Vol 139 (2) ◽  
pp. 219-224 ◽  
Author(s):  
Andrea Diaz De Vivar ◽  
Marilyn Dawlett ◽  
Jian-Ping Wang ◽  
Annie Jack ◽  
Yun Gong ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Clinical Performance ◽  
Close Monitoring ◽  
High Grade ◽  
Papanicolaou Test ◽  
Hybrid Capture ◽  
Hybrid Capture 2 ◽  
Test Result

Context Women who have been treated for high-grade cervical or vaginal intraepithelial neoplasia (CIN or VAIN) or invasive carcinoma are at risk for recurrent/persistent disease and require long-term monitoring. The role of human papillomavirus (HPV) testing in this setting is unclear. Objective To evaluate the clinical performance of the Hybrid Capture 2 (HC2) HPV test for recurrent/residual high-grade CIN or VAIN in patients with a posttherapy abnormal squamous cells of undetermined significance (ASC-US) Papanicolaou test result. Design We reviewed the follow-up data on 100 patients who had an ASC-US Papanicolaou test and HC2 HPV results after treatment for high-grade CIN/VAIN or carcinoma. Human papillomavirus genotyping was performed for women with a negative HC2 result whose follow-up biopsy revealed CIN/VAIN 2+. Results The patients' mean age was 47 years. The HC2 test result was positive in 33% of the patients. Follow-up biopsy was available for 17 of these patients (52%) and for 25 of the 67 patients (37%) with a negative HC2 result. A total of 5 of the patients (29%) with a positive HC2 result and 2 of the patients (8%) with a negative HC2 result had CIN/VAIN 3 on follow-up biopsy, a statistically insignificant difference (P = .10). Human papillomavirus 16/18 genotypes were detected in the CIN/VAIN 2+ lesions of 5 patients with a negative HC2 result. Conclusion HC2 yielded a false-negative rate of 8% for CIN 3. HC2 testing therefore may not be sufficient for triage of patients with an ASC-US Papanicolaou test result. Patients with ASC-US during long-term posttherapy follow-up need close monitoring, with colposcopic evaluation if clinically indicated.

Anal Human Papillomavirus Testing with Digeneʼs Hybrid Capture 2 Using Two Different Sampling Methods

2008 ◽  
Vol 51 (1) ◽  
pp. 62-66 ◽  
Author(s):  
Florian Roka ◽  
Julia Roka ◽  
Andreas Trost ◽  
Horst Schalk ◽  
Christian Zagler ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Sampling Methods ◽  
Hybrid Capture ◽  
Human Papillomavirus Testing ◽  
Hybrid Capture 2

scholarly journals Low prevalence of high risk human papillomavirus in normal oral mucosa by hybrid capture 2

2008 ◽  
Vol 39 (1) ◽  
Author(s):  
Maria del Refugio González-Losa ◽  
Luis Manzano-Cabrera ◽  
Florencio Rueda-Gordillo ◽  
Sandra E. Hernández-Solís ◽  
Marylin Puerto-Solís
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Oral Mucosa ◽  
Hybrid Capture ◽  
Normal Oral Mucosa ◽  
Hybrid Capture 2 ◽  
Low Prevalence

scholarly journals Prevalence, incidence, and distribution of human papillomavirus types in female sex workers in Kenya

2020 ◽  
Vol 31 (2) ◽  
pp. 109-118
Author(s):  
Kristen Sweet ◽  
Claire Bosire ◽  
Busola Sanusi ◽  
Carly J Sherrod ◽  
Jessie Kwatampora ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Sex Workers ◽  
Female Sex Workers ◽  
Sub Saharan Africa ◽  
Hiv Positive ◽  
Female Sex ◽  
Hpv Prevalence ◽  
Hiv Negative

Female sex workers (FSWs) have a notably high risk of acquiring human papillomavirus (HPV) infections. Relatively few studies address the type-specific prevalence and incidence of HPV among FSWs in sub-Saharan Africa. FSWs (n = 348) attending the Korogocho clinic in Nairobi, Kenya participated from August 2009 to March 2011. HPV DNA was detected using the SPF10-LiPA25 PCR assay. Baseline prevalence of HPV infection and cervical dysplasia were calculated, stratified by HIV-serostatus. Incidence rate (IR) of infection was calculated as number of new infections from baseline over person-months among 160 HPV-negative participants with complete 12-month follow-up. Baseline HPV prevalence was 23.6% for any HPV and 20.4% for high-risk HPV (hrHPV) types. Most prevalent types were HPV52 (10.1%), HPV35 (2.3%), and HPV51 (2.3%). A quarter (24%) of participants were HIV-positive. HPV prevalence was higher in HIV-positive (32.1%) than HIV-negative (20.8%) participants. hrHPV prevalence was higher in HIV-positive (27.4%) than HIV-negative (18.2%) women. During follow-up, HPV IR was 31.4 (95% CI: 23.8–41.5) for any HPV and 24.2 (95% CI: 17.9–32.8) for hrHPV types. HPV52 had the highest IR (6.0; 95% CI: 6.5–10.3). Overall HPV and hrHPV prevalence were lower than expected, but both prevalence and incidence were higher in HIV-positive than in HIV-negative women.

Sign in / Sign up

Export Citation Format

Share Document